相关实验视频
Updated: Jan 9, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
877
蒂尔泽帕提德与塞马格卢提德:GLP-1环境中的临床决策
Alvin Mondoh1,2, Michael Crotty2, Carel W le Roux1,2
1Diabetes Complications Research Centre, Conway Institute of Biomedical and Biomolecular Research, University College Dublin, Dublin, Ireland.
Expert opinion on pharmacotherapy
|December 6, 2025
概括
塞马格卢提德和提泽帕提德是主要的肥胖药物. 塞马格卢提德有助于心脏健康,而提泽帕提德为慢性肥胖管理提供了优越的减肥和代谢改善.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 肥胖是一种具有全球健康影响的慢性疾病.
- 类似葡萄糖-1受体激活剂 (GLP-1RAs) 和双GIP/GLP-1受体激活剂 (GIP-1RAs) 是已确立的肥胖治疗方法.
- 本综述侧重于用于管理肥胖症的西马格卢提德和蒂尔泽帕提德.
研究的目的:
- 为肥胖管理提供赛马格卢提德和蒂尔泽帕提德的比较分析.
- 为了指导临床医生评估减肥,代谢和心血管效益.
- 讨论机制上的差异,耐受性和现实世界的实施.
主要方法:
- 使用PubMed和谷歌学者进行文学搜索.
- 对主要国际心脏病学和内分泌学出版物的审查 (2020-2025年).
- 来自关键临床试验 (STEP,SELECT,SURMOUNT,SUMMIT) 的数据综合.
主要成果:
- 塞马格卢提德提供了显著的心血管保护.
- 蒂尔泽帕提德显示了更大的减肥和更广泛的代谢益处.
- 这两种药物都是当前肥胖药物治疗的基础.
结论:
- 塞马格卢提德和蒂尔泽帕提德对于管理肥胖症作为慢性疾病至关重要.
- 临床医生必须考虑每个药物的独特益处,以获得精确的患者护理.
- 持续的药理管理对于持久的肥胖治疗结果至关重要.
相关概念视频
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Dipeptidyl Peptidase 4 Inhibitors
559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Oral Hypoglycemic Agents: Biguanides and Glitazones
565
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
565
Drug Products: Biologics, Biosimilars and Interchangeables
219
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
219
Oral Hypoglycemic Agents: Sulfonylureas
728
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
728

